Newsbenzinga
Sanofi Discontinues Amlitelimab Development In Atopic Dermatitis, Will Not Submit For Global Regulatory Reviews After Strategic Pipeline Assessment
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…